|1.||Emoto, Makoto: 6 articles (08/2011 - 04/2003)|
|2.||Kawarabayashi, Tatsuhiko: 6 articles (08/2011 - 04/2003)|
|3.||Folkman, Judah: 6 articles (04/2011 - 04/2003)|
|4.||Satchi-Fainaro, Ronit: 5 articles (07/2011 - 03/2004)|
|5.||Beecken, W D: 4 articles (10/2001 - 09/2000)|
|6.||Mitchell, Christopher A: 3 articles (10/2011 - 12/2005)|
|7.||D'Amato, Robert J: 3 articles (04/2011 - 04/2002)|
|8.||Svensson, Asa: 3 articles (05/2008 - 05/2002)|
|9.||Bäckman, Ulrika: 3 articles (05/2008 - 05/2002)|
|10.||Bigda, Jacek: 3 articles (07/2007 - 09/2005)|
04/15/1994 - "AGM-1470 is a potent angiogenesis inhibitor that is very effective in inhibiting endothelial cell proliferation in both in vitro and in vivo models and that prevents tumor growth in vivo. "
01/01/2001 - "However, when TNP-470 was administered in the setting of microscopic disease 12 hr following tumor cell inoculation, treated mice had a significantly improved tumor-free survival at 12 weeks (P < 0.001), and overall survival at 45 weeks (P < 0.001), compared to control animals. "
01/01/1999 - "TNP-470 administration resulted in a significant reduction of the tumor growth rate and microvascular counts, and of the fraction of viable tumor cells, compared to controls. "
07/01/1998 - "Furthermore, the sustained effect of TNP-470 induced tumor dormancy and consequently improved the survival of the animals. "
01/01/1998 - "This indicates that excision of tumor created more favourable conditions for angiogenesis and that the dose of TNP-470 should be increased to be effective in such conditions."
|2.||Neoplasm Metastasis (Metastasis)
05/01/1996 - "In this study, we have assessed the effects of AGM-1470, an antiangiogenic agent, and pentosan polysulphate (PPS), an agent that abrogates the effects of FGFs, on tumour growth and metastasis produced by these FGF-transfected MCF-7 cells. "
01/01/2012 - "Exploration of the molecular mechanisms by which TNP-470 inhibited growth and metastasis of CCA cell lines demonstrated expression of c-MYC, MMP2 and MMP9 to be decreased in TNP-470 treated cells. "
04/01/2007 - "TNP-470 prolonged survival and reduced liver metastases. "
12/01/2005 - "TNP-470 plus CTX showed synergetic effect on inhibiting metastasis on lung surface with a Q value of 1.21. "
02/01/2003 - "Treatment with the antiangiogenic reagent TNP-470 suppressed postoperative progression of pulmonary metastasis. "
09/01/2000 - "Our results indicate that antiangiogenic therapy with TNP-470 is equally effective in advanced superficial and invasive bladder carcinoma models in mice. "
08/01/1999 - "Multi-institutional study of the angiogenesis inhibitor TNP-470 in metastatic renal carcinoma."
02/01/2004 - "These results suggest that the clinical application of TNP-470 may be one of the possible treatments for the CDDP-resistant ovarian carcinomas."
09/01/2000 - "The in vitro proliferation of both bladder carcinoma cell lines was also inhibited by TNP-470. "
01/01/1999 - "AGM-1470 was administered at a dose of 30 mg/kg every other day for 6 weeks in group 1 and at 15 mg/kg once a week for 6 weeks in group 3. This treatment was commenced at 21 weeks after the start of BBN treatment, when tumorigenesis was apparent in all rat bladders; approximately 70-80% of the tumours were carcinomas. "
|4.||Melanoma (Melanoma, Malignant)
02/01/2004 - "It was found finally that TNP-470 given in the vicinity of the growing tumour can cause complete remission of the melanoma in hamsters treated in this way. "
01/01/2002 - "Thus, Ab melanoma can be effectively cured with TNP-470 angiogenesis inhibitor when the substance is applied locally."
02/01/2004 - "In our previous studies it was found that the angiogenesis inhibitor TNP-470 given to transplantable melanoma-bearing hamsters can decrease the rate of the tumour growth, although the survival time of the animals treated was not significantly affected. "
01/01/1998 - "In this study, we examined the effect of the angiogenesis inhibitor TNP-470 on a fast growing melanoma in hamsters. "
01/01/2006 - "The atypical pattern of cell death in B16F10 melanoma cells treated with TNP-470."
01/01/2000 - "Our in vitro findings suggest that this angiogenesis inhibitor, TNP-470, might be a novel therapeutic agent for uterine carcinosarcoma. "
01/08/2004 - "Carcinosarcoma-induced endothelial cells tube formation through KDR/Flk-1 is blocked by TNP-470."
04/01/2003 - "We speculate that TNP-470 may be a useful agent for adjuvant therapy in patients with advanced or recurrent uterine carcinosarcomas. "
04/01/2003 - "These results suggest that TNP-470 may inhibit the growth of human uterine carcinosarcoma in vivo. "
04/01/2003 - "The growth-inhibitory and anti-angiogenic effects of TNP-470 were examined after inoculating a human uterine carcinosarcoma cell line, FU-MMT-1, in nude mice. "
|6.||Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)
|9.||Suramin (Suramin Sodium)
|1.||Drug Therapy (Chemotherapy)
|2.||Heterologous Transplantation (Xenotransplantation)
|3.||Transplantation (Transplant Recipients)